GENETIC STRATEGIES FOR DRUG TARGETING

该小型企业创新研究第二阶段项目旨在 调查开发新生物系统的使用情况 共同标记基因在转化细胞中的表达以控制生长 以及活组织中细胞的特征。建立在我们成功的基础上 第一阶段的努力，拟议的研究将提供突破 需要推进重组基因的新的有前途的医疗用途。在……里面 第一阶段，Marker gene Technologies，Inc.确定了 该技术通过制备新的半乳糖苷和头孢菌素 常用生长调节剂、药物和酶抑制剂的结合物，用于 给动物细胞或细菌注射含有β- 半乳糖苷酶(Lac Z)或氨苄西林耐药(β-内酰胺酶，Amp) 基因作为基因融合标记。这些新的结合物利用了这些融合 转化细胞中影响药物传递和控制的系统 选定的生物学特性。 在第二阶段，新的生物系统将在体内实施，用于 它们能够对细胞生长和细胞生长产生特定和局部的影响 以细胞或组织特异性的方式传递激活的药物。在……里面 特别是，这些共轭化合物将在有意义的 癌症和增生性疾病的基因和免疫治疗的医学领域 疾病治疗。 建议的商业应用： 这个项目的成功带来了巨大的商业可能性。 在遗传病的医学干预领域，基因和 免疫疗法治疗癌症，生物技术生产新产品 细胞培养系统中的蛋白质和药物，以及细菌筛选 战略。此外，它还提供了新的信息和技术 用于基础细胞生物学研究。

This Small Business Innovation Research Phase II project aims to investigate the use of developing new biological systems employing common marker gene expression in transformed cells to control the growth and character of cells in living tissue. Building on our successes in the Phase I effort, the proposed research will provide breakthroughs needed to advance new promising medical uses of recombinant genes. In Phase I, Marker Gene Technologies, Inc. established the feasibility of this technology by preparing new galactoside and Cephalosporin conjugates of common growth regulators, drugs and enzyme inhibitors, for administration to animal cells or bacteria that contain either the beta- galactosidase (lac Z) or ampicillin resistance (beta-lactamase, amp) genes as gene fusion markers. These new conjugates utilized these fusion systems in transformed cells to affect drug delivery and control selected biological properties. In Phase II, the new biological systems will be implemented in vivo for their ability to cause specific and localized effects on cell growth and to deliver activated drugs in a cell- or tissue-specific manner. In particular, the conjugates will be further tested in the significant medical areas of gene and immuno-therapy for cancer and proliferative diseases treatment. PROPOSED COMMERCIAL APPLICATION: The success of this project opens up enormous commercial possibilities in the fields of medical intervention in genetic diseases, gene and immuno- therapy for cancer treatment, biotechnological production of new proteins and drugs in cell-culture systems, and bacterial screening strategies. In addition, it contributes new information and techniques for basic cell-biology research.